The use of social media is now so widespread that professional healthcare organizations have developed guidelines for its use. One of the most recent organizations to create utilization guidelines is the American Congress of Obstetricians and Gynecologists (ACOG), which released its guidelines in April 2015. Other guidelines are available from state medical boards, and the American Medical Association released a statement on the topic in 2010. The American Nurses Association (ANA) released a tool kit, which contain the ANA’s social networking principles, tips for nurses using social media, social media webinar, and a fact sheet.
ANA’s principles include not transmitting or posting identifiable patient information, observing patient-nurse boundaries, and being aware that colleagues and others have the ability to view what is posted. Nurses should utilize privacy settings and ideally, have separate personal and professional online accounts. Nurses also need to bring harmful content to the attention of appropriate individuals or authorities. The ANA notes that misuse of social media can not only damage the individual nurse’s reputation, but may damage the reputation of the nursing profession as well. The toolkit is available at http://www.nursingworld.org/socialnetworkingtoolkit.aspx.
Social Media: Risks and Benefits
The use of social media is now so widespread that professional healthcare organizations have developed guidelines for its use.
The use of social media is now so widespread that professional healthcare organizations have developed guidelines for its use. One of the most recent organizations to create utilization guidelines is the American Congress of Obstetricians and Gynecologists (ACOG), which released its guidelines in April 2015. Other guidelines are available from state medical boards, and the American Medical Association released a statement on the topic in 2010. The American Nurses Association (ANA) released a tool kit, which contain the ANA’s social networking principles, tips for nurses using social media, social media webinar, and a fact sheet.
ANA’s principles include not transmitting or posting identifiable patient information, observing patient-nurse boundaries, and being aware that colleagues and others have the ability to view what is posted. Nurses should utilize privacy settings and ideally, have separate personal and professional online accounts. Nurses also need to bring harmful content to the attention of appropriate individuals or authorities. The ANA notes that misuse of social media can not only damage the individual nurse’s reputation, but may damage the reputation of the nursing profession as well. The toolkit is available at http://www.nursingworld.org/socialnetworkingtoolkit.aspx.
Glecirasib Elicits Responses With Manageable Safety in Pretreated KRAS G12C Mutated NSCLC
May 14th 2024Glecirasib resulted in durable responses with a manageable safety profile for pretreated advanced non-small cell lung cancer with KRAS G12C mutations.
What New Cancer Drugs Were Approved in 2023?
January 1st 2024In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.
Adverse Effect Management for Immunotherapies in Advanced Endometrial Cancer
May 13th 2024Tiffany Bostwick, P.A., discussed the importance of communication and education around adverse effects for both oncology nurses and for patients with advanced endometrial cancer who are treated with immunotherapies.
Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies
December 14th 2023Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.
Dostarlimab/Chemo Receives Priority Review to Expand Indication in Endometrial Cancer
May 12th 2024Dostarlimab plus chemotherapy has been granted priority review from the FDA to expand its indication to all adult patients with primary advanced or recurrent endometrial cancer.
CTX-009 Plus Paclitaxel Receives Fast Track Designation for Pretreated Biliary Tract Cancer
May 11th 2024The FDA granted fast track designation to CTX-009 plus paclitaxel for pretreated metastatic or locally advanced biliary tract cancer.
Glecirasib Elicits Responses With Manageable Safety in Pretreated KRAS G12C Mutated NSCLC
May 14th 2024Glecirasib resulted in durable responses with a manageable safety profile for pretreated advanced non-small cell lung cancer with KRAS G12C mutations.
What New Cancer Drugs Were Approved in 2023?
January 1st 2024In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.
Adverse Effect Management for Immunotherapies in Advanced Endometrial Cancer
May 13th 2024Tiffany Bostwick, P.A., discussed the importance of communication and education around adverse effects for both oncology nurses and for patients with advanced endometrial cancer who are treated with immunotherapies.
Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies
December 14th 2023Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.
Dostarlimab/Chemo Receives Priority Review to Expand Indication in Endometrial Cancer
May 12th 2024Dostarlimab plus chemotherapy has been granted priority review from the FDA to expand its indication to all adult patients with primary advanced or recurrent endometrial cancer.
CTX-009 Plus Paclitaxel Receives Fast Track Designation for Pretreated Biliary Tract Cancer
May 11th 2024The FDA granted fast track designation to CTX-009 plus paclitaxel for pretreated metastatic or locally advanced biliary tract cancer.
Latest Conference Coverage
Apalutamide/ADT Confers 100% Recurrence-Free Survival in High-Risk Prostate Cancer
TAR-200 Leads to Lasting Responses in BCG-Unresponsive Bladder Cancer
UGN-102 Produces Comparable Responses Regardless of Surgery in NMIBC Subset
Verbal Workflow for Tocilizumab Orders Results in More Timely CRS Intervention